Korea Institute of Science and Technology

Neurobiogen Co., Ltd.

Megabiowood Co., Ltd

Hyun Ah Choo

Ae Nim Pae

Yun Kyung Kim

Ghil Soo Nam

Jong-Hyun Park

Dong Jin Kim

Jun Young Heo

Ji Won Choi

Kyung Il Choi

Gyo Chang Keum

Jung Hyun Kim

ChangJoon Justin Lee

Ki Duk Park

Yong Koo Kang

Seul Ki Yeon

Sun Joon Min

Hyo Jung Song

Jae Kyun Lee

Seon Hee Seo

Min Ho Nam

Bo Ko Jang

Eun Ji Ju

Seon Mi Jo

Eun Kyoung Bang

Sung Su Lim

Hye Whon Rhim

Seung Yeol Nah

Jong-hyun Park

Ahmed A Elbatrawy

Changjoon Justin Lee

Disclosed are a compound with near-infrared fluorescence that selectively binds to tau aggregates, a method for preparing the same, a tau-targeting near-infrared fluorescent probe including the compound, a composition for detecting a tau fiber protein containing the near-infrared fluorescent probe as an active ingredient, and the use of the composition for the diagnosis of tauopathy. In particular, the compound does not bind to an amyloid beta protein and has high selectivity to a tau aggregate, specifically reported as an etiology of the initial state of tauopathy, thus being useful as a near-infrared fluorescent detector for detecting a tau fiber protein for early diagnosis of a tauopathy including Alzheimer's disease.

Compounds useful as near-infrared fluorescent probes selectively binding to tau aggregates and method of preparing the same

The present disclosure relates to an &#x3b1;-aminoamide derivative compound and a pharmaceutical composition containing the same. According to various embodiments of the present disclosure, provided is a therapeutic agent which can overcome the disadvantages of existing drugs used as a MAO-B inhibitor and, specifically, reversibly inhibits MAO-B through a non-covalent bond so as to alleviate or eliminate the side effects of the existing drugs which exhibit a therapeutic effect by irreversibly acting via a covalent bond with MAO-B. Particularly, a new compound having superior stability and efficacy compared to the existing reversible MAO-B inhibitors may be provided.

Alpha-aminoamide derivative compound and pharmaceutical composition comprising same

The present disclosure relates to an &#x3b1;-aminoamide derivative compound and a pharmaceutical composition containing the same, for treating a neurodegenerative diseases.

The present invention relates to a 6-pyrazolylamido-3-substituted azabicyclo[3.1.0]hexane derivatives useful as calcium channel blockers, pharmaceutically acceptable salts thereof and medical use of the calcium channel inhibiting effect of the compounds for treatment of diseases.

6-pyrazolylamido-3-substituted azabicyclo[3.1.0]hexane compounds as calcium channel inhibitors

The present invention relates to a pharmaceutical composition containing one or more quinazoline compounds as an active ingredient, which has antagonistic activity against serotonin 5-HTA and is effective for the prevention and treatment of central nervous system (CNS) diseases, including emesis, nausea, alcoholism, drug abuse, depression, compulsive neurosis, anxiety, seizure, Alzheimer's disease, Parkinson's disease, Huntington's chorea, psychosis, schizophrenia, suicidal tendency, sleep disorder, appetite disorder and migraine.

Pharmaceutical compositions containing quinazoline derivatives for treating as serotonin receptor antagonist

Growing community of inventors

Seoul, South Korea

Hyun Ah Choo